Is Your Paper Ready for Nature Reviews Drug Discovery? The Invitation-Only Reality

Nature Reviews Drug Discovery editors track both the academic literature and the pharmaceutical pipeline closely. According to the journal's editorial model, invitation candidates fall into two main categories: academic researchers who have published foundational work in a target area or therapeutic mechanism, and pharmaceutical or biotech industry scientists who have led or closely participated in clinical programs that reached a decision point worth analyzing.

The drug discovery literature is different from basic science in one important respect: the editorial team values industry experience and clinical translational knowledge as highly as academic citation prominence. A researcher who has published 20 papers on a kinase target in journals like JACS or Nature Chemical Biology and also consulted on or led an industry target validation program is a stronger invitation candidate than a researcher with the same academic record but no translational connection.

There is no structured pre-submission inquiry form. Researchers who want to approach the journal should email the editorial office with a two-paragraph proposal covering the topic scope, the author team's qualifications, and why this synthesis is needed now rather than being a duplicate of a recent review in the area.

In our pre-submission review work with manuscripts targeting high-impact drug discovery and pharmacology journals, five patterns generate the most consistent desk rejections worth knowing before submission.

Target validation studies without disease-relevant human biology.

According to Nature Chemical Biology's author guidelines, the journal expects target validation studies to demonstrate relevance to human disease biology rather than to characterize a target interaction in an isolated biochemical or cell-free system. We see this pattern in manuscripts we review more frequently than any other drug discovery-specific failure. Papers that demonstrate potent in vitro inhibition of a target without connecting the pharmacological effect to a disease-relevant cellular or animal model face desk rejection before external review. In our experience, roughly 45% of target biology manuscripts we review are framed around biochemical potency without human-relevant target validation.

Medicinal chemistry papers without selectivity profiling.

Per Journal of Medicinal Chemistry's author guidelines, manuscripts reporting new chemical series or optimized lead compounds are expected to include selectivity profiling across closely related targets and key off-target assays to establish that the observed pharmacological activity is on-target. We see this in roughly 40% of medicinal chemistry manuscripts we review, where a new compound series shows potent activity against the primary target without any selectivity data demonstrating that the activity is not explained by off-target effects. Editors consistently reject papers where the medicinal chemistry optimization is reported without selectivity context.

ADMET or pharmacokinetic gaps in drug candidate papers.

Editors consistently flag manuscripts where a drug candidate or chemical probe is reported with in vitro and in vivo efficacy data but without the pharmacokinetic profile needed to interpret the in vivo results. In practice, desk rejection tends to occur for papers where the route, dose, and dosing interval used in animal efficacy experiments are not supported by pharmacokinetic data showing adequate compound exposure. In our experience, roughly 35% of drug discovery manuscripts we review have a pharmacokinetic gap where the in vivo efficacy data is reported without the exposure data needed to confirm the mechanism is on-target at the doses used.

Phenotypic screening hits reported without target deconvolution.

Nature Chemical Biology and Cell Chemical Biology editors look for target deconvolution data supporting the proposed mechanism of action when papers report findings from phenotypic screens. Papers where a new compound is shown to produce a cellular phenotype without identifying the molecular target responsible face significant revision requests or rejection. According to Nature Chemical Biology's guidelines, chemical biology papers are expected to establish a mechanistic connection between the chemical entity and the biological effect rather than treating phenotypic activity as a complete finding.

In vivo efficacy claims without appropriate statistical power.

In our analysis of drug discovery manuscripts we review, roughly 40% of animal pharmacology papers have inadequate group sizes for the primary efficacy endpoint, or present statistical analysis that is not appropriate for the data type and experimental design. Per Journal of Medicinal Chemistry's and Nature Chemical Biology's reproducibility requirements, animal studies are expected to include group size justification based on expected effect size, and statistical methods are expected to be appropriate for the design. In practice, desk rejection tends to occur for papers where the primary in vivo efficacy finding is supported by a single experiment with n of three to five per group without power calculation or independent replication.

Before submitting drug discovery primary research, a pre-submission framing check identifies whether the target validation, selectivity profiling, and pharmacokinetic evidence meet the editorial bar at Nature Chemical Biology, Journal of Medicinal Chemistry, or Cell Chemical Biology.